 |
|
|
Best Global M&A house: Morgan Stanley |
|
|
Also nominated: Goldman Sachs and JPMorgan |
Euromoney catches up with Rob Kindler, vice-chairman and global head of M&A at Morgan Stanley, shortly after his return to New York from a celebration dinner for Sanofi-Aventis’s $20.9 billion acquisition of Genzyme, the deal of the year in the healthcare sector. It was noteworthy in several aspects, not least that it began as a hostile, unsolicited offer. Such deals are still quite rare as the recovery in the M&A market begins to gather momentum and acquirers are cautious about being drawn into bidding contests.
Access intelligence that drives action
To unlock this research, enter your email to log in or enquire about access
